Apellis Pharmaceuticals Inc (APLS) — Capital Reinvestment Ratio
Apellis Pharmaceuticals Inc (APLS) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow ($108.47 Million) in capital expenditures ($148.00K). See APLS equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Apellis Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)
This chart tracks Apellis Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does Apellis Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Apellis Pharmaceuticals Inc (2025–2025)
Year-by-year Capital Reinvestment Ratio for Apellis Pharmaceuticals Inc from 2025 to 2025. For live market cap and broader valuation context, see Apellis Pharmaceuticals Inc market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $45.33 Million | $313.00K | — |